• EXO-OC ovarian cancer screening test demonstrated 100% sensitivity for early-stage disease
• CAR-exosome therapy program showed promising results, killing 88% of triple-negative breast cancer and non-small cell lung cancer cells in vitro
• Expanded EXO-NET research tool business and published neuCA15-3 data in a peer-reviewed journal

INOVIQ Ltd (ASX:IIQ) is a leader in exosome technology focused on advancing next-generation diagnostics and therapeutics that transform cancer care and improve patient outcomes. The company made significant progress during FY25, achieving key milestones across its commercial, research and development, and corporate activities. On the commercial front, INOVIQ grew its EXO-NET customer base and revenue, and expanded the product portfolio with the development and validation of NEURO-NET for isolating brain-derived exosomes. In research and development, the company's EXO-OC ovarian cancer screening test demonstrated 100% sensitivity for early-stage disease, the CAR-NK-exosome therapeutic program achieved 88% cell death in triple negative breast cancer and non-small cell lung cancer cells in vitro, and the neuCA15-3 breast cancer monitoring test completed disease specificity testing. Corporately, INOVIQ appointed key leaders, including Mary Harney as Non-Executive Director and Dr Emma Ball as Chief Commercial Officer, and established a Medical and Scientific Advisory Board. Financially, the company ended FY25 with $6.5 million in cash but reported a net loss of $6.9 million as it continued to invest heavily in its programs.

INOVIQ expects to deliver key milestones in FY26, including commercial expansion of its EXO-NET research tools, development progress across its exosome diagnostic and therapeutic programs, and strategic partnerships to accelerate commercialisation of its diagnostic technologies.

INOVIQ is well-positioned for future growth, with an experienced leadership team and a promising multi-product pipeline. The company's FY26 priorities include expanding the EXO-NET business, advancing EXO-OC toward commercialisation, progressing CAR-exosome therapy, and forming strategic partnerships to accelerate diagnostic technology commercialisation.